The European Commission has granted a marketing authorisation for Trecondi (treosulfan), as part of conditioning treatment prior to alloHSCT in adult patients with malignant and non-malignant diseases and in paediatric patients with malignant diseases.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe